Surgery Today
Cure8 research brief
Why This Matters
The study highlights factors linked to needing another operation after ileocecal resection for Crohn’s disease and suggests postoperative biologic therapy may lower long-term reoperation risk. That directly affects treatment planning after surgery.
Who Should Pay Attention
Post-surgery patients with Crohn’s disease, gastroenterologists and colorectal surgeons, and researchers studying postoperative recurrence and biologic prophylaxis.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
The study is a retrospective cohort with median follow-up around 6+ years and reports associations (hazard ratios) rather than causal proof.
The finding that postoperative biologic prophylaxis was protective supports current interest in using biologics after surgery to reduce re-resection, but treatment decisions depend on individual clinical context and guideline recommendations.
If you are a patient planning or recovering from ileocecal resection, discuss with your gastroenterologist or surgeon whether postoperative biologic prophylaxis is appropriate for your case; clinicians may consider prior anti-TNF exposure and history of multiple surgeries or perianal disease when assessing recurrence risk.
This summary is grounded in the article abstract and metadata provided; Cure8 did not review the full subscription content PDF.
Keep In Mind
This is a retrospective observational study reporting associations; it does not prove causation. The article preview is subscription content — the summary is based on the provided abstract and metadata, not a full-text appraisal.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationSurgery Today
AuthorsYuhua Huang, Zhizhen Qin, Danhua Yao +4 more
InstitutionShanghai Ninth People's Hospital
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedJul 31, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.